This generally well-conducted review concluded that symptomatic venous thromboembolism developed prior to hospital discharge in approximately one in 100 patients undergoing knee arthroplasty and one in 200 patients undergoing hip arthroplasty who received venous thromboembolism prophylaxis. The conclusions reflect the results presented but given the substantial variation between studies, the applicability of the overall pooled results is questionable.
Authors' objectives
To estimate symptomatic venous thromboembolism (venous thromboembolism) event rates prior to hospital discharge in patients undergoing total or partial hip arthroplasty and total or partial knee arthroplasty.
Searching
MEDLINE, EMBASE, and the Cochrane Library were searched with no language restrictions up to September 2011; search terms were reported. The search strategy was available in an online appendix. Bibliographies of relevant articles were searched. Authors working in the field contacted for additional studies.
Study selection
Randomised controlled trials (RCTs) that evaluated venous thromboembolism prophylaxis regimens, and observational studies of patients receiving venous thromboembolism prophylaxis, that reported confirmed postoperative symptomatic venous thromboembolism that occurred before hospital discharge following total or partial arthroplasty of the knee or hip, were eligible for inclusion. Eligible inpatients had to be over 18 years of age. Eligible venous thromboembolism prophylactic regimens were low-molecular weight heparin or direct and indirect Xa and IIa factor inhibitors. Deep vein thrombosis had to be confirmed by venography or ultrasonography (with or without impedance plethysmography). Clinical diagnosis of pulmonary embolism had to be confirmed by perfusion/ventilation scintigraphy, pulmonary angiography, spiral computed tomography, or autopsy.
Across the included studies, the proportion of women ranged from 12 to 85%, mean age ranged from 58 to 74 years, and mean duration of post-surgical follow-up ranged from eight to 35 days. The prophylactic regimens varied considerably across studies, although enoxaparin was the most commonly evaluated drug.
Two reviewers selected studies for the review.
Assessment of study quality
Two reviewers evaluated study quality using GRADE (Grading of Recommendations Assessment, Development and Evaluation). Allocation concealment, blinding, sparse data, attrition bias, indirectness, potential measurement bias, and potential conflict of interest were assessed at the study level. Risk of bias, imprecision, inconsistency, and indirectness was assessed at the group level.
Data extraction
The number of events were extracted by two independent reviewers. Events rates and 95% confidence intervals (CIs) were calculated.
Methods of synthesis
Pooled event rates and 95% confidence intervals were calculated using a fixed-effect Mantel-Haenszel method weighted by standard error for the overall analyses, and the random-effects DerSimonian and Laird model for stratified analyses when substantial heterogeneity was observed. Heterogeneity was assessed using I 2 ; 50% was considered substantial heterogeneity.
